[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …
M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)
S Morita, T Hirashima, K Hagiwara, T Hida… - Journal of Clinical …, 2008 - ascopubs.org
8101 Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene
are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (EGFR …
are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (EGFR …
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
SH Cho, LC Park, JH Ji, S Park, DW Hwang… - Cancer chemotherapy …, 2012 - Springer
Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …
PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
相关搜索
- nsclc patients egfr mutation
- tumor response egfr mutation
- egfr mutations lung cancer
- shrinkage pattern egfr mutation
- shrinkage pattern tumor response
- shrinkage pattern lung cancer
- survival outcome egfr mutation
- shrinkage pattern survival outcome
- tumor response lung cancer
- tumor response survival outcome
- survival outcome lung cancer
- egfr mutations gefitinib treatment
- egfr mutations relative abundance
- gefitinib treatment lung cancer
- relative abundance lung cancer
- egfr tkis clinical outcome